In this issue of the Archives, Downing et al1 present a case report about how a pharmaceutical manufacturer successfully avoided generic competition for one of its blockbuster drugs for more than a decade. The use of patent infringement lawsuits to delay generic competition, a practice called “evergreening,” is common and perhaps well known.
However, for fenofibrate, Abbott Laboratories devised a novel and especially clever approach: the manufacturer reformulated the drug at a slightly different dose, gained approval on the basis of claims of bioequivalence, and then avoided competition because the minor differences in dose prohibited generic substitution. In 2000, for instance, Abbott used efficacy and safety data from previously submitted clinical trials in its “new” drug application and, on the basis of the results of 4 small pharmacokinetic studies, claimed bioequivalence between the approved formulation (Tricor-1 capsules with 67-, 134-, and 200-mg doses) and the new formulation (Tricor-2 tablets with 54-mg and 160-mg doses). No new clinical trials of triglyceride lowering were conducted. In 2001, the manufacturer switched exclusively to sales of Tricor-2 tablets, so that patients taking fenofibrate had to be switched over to Tricor-2 doses during the 6 months before the generic versions of Tricor-1 doses were approved by the Food and Drug Administration. As a result of the minor change in dose, pharmacists filling Tricor-2 prescriptions could not substitute generic versions of Tricor-1 when they finally became available in early 2002, despite the fact that the manufacturer had won approval on the basis of pharmacokinetic evidence for bioequivalence. The manufacturer used these methods repeatedly to avoid generic competition through December 2011.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.